64 results about "Adenocarcinoma pancreas" patented technology

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The present invention relates to methods for improving the diagnosis of pancreatic and ampullary adenocarcinomas by making use of specific mi RNA biomarkers and / or mi RNA classifiers.

The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a / Arf, Ink4a, Arf, p53, Smad4 / Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.

The present invention concerns materials and methods for identifying and classifying pancreatic ductal adenocarcinoma (PDAC) precursors or intraductal papillary mucinous neoplasm (IPMN) using messenger RNAs, microRNAs, long non-coding RNAs, radiomic features, radiologic measures of abdominal / visceral obesity, and combinations thereof, as diagnostic markers for integration with clinical management and interventions for personalized care.

A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.

The invention related to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.

The invention relates to the field of biological medicines, in particular to a single-chain antibody specifically bound with CLDN18.2 and a chimeric antigen receptor (CAR) containing the single-chain antibody. The invention also relates to reconstructed immune cells expressing the CAR, or co-expressing the CAR and a further bioactive molecule (e.g., a PD-1 antibody or mIL-15), nucleic acid molecules encoding such CAR or co-expressed molecules, and methods of preparing the reconstructed immune cells. The invention also relates to application of the CAR and the immune cells in preventing and / or treating cancers such as gastric cancer, gastric adenocarcinoma and pancreatic cancer and a method for preventing and / or treating the cancers such as the gastric cancer, the gastric adenocarcinoma and the pancreatic cancer.

The application relates to methods based on modulating pancreatic and / or gastrointestinal microbiota and related antifungal compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.

The invention relates to the field of clinical diagnosis of pancreatic adenocarcinoma, in particular to a gene marker for prognosis of pancreatic adenocarcinoma. The gene marker is an m5C regulatory gene. The invention further discloses application of the expression quantity of the m5C regulatory gene in prognosis of pancreatic adenocarcinoma. The gene marker for detecting pancreatic adenocarcinoma has the advantages of safety and noninvasiveness, and is high in detection acceptability even for asymptomatic population; RNA sources are wide, and a detection blind area in iconography does not exist; the gene marker is high in accuracy, has relatively high sensitivity and specificity to early pancreatic adenocarcinoma, and is suitable for early screening of pancreatic adenocarcinoma; and theoperation is convenient, and it is easy to dynamically monitor the recurrence and metastasis of pancreatic adenocarcinoma. The gene marker can be combined with other clinical indexes, so that more accurate judgment is provided for screening, diagnosis, treatment and prognosis of pancreatic adenocarcinoma.

An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and / or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and / or amelioration and / or treatment of pancreatic adenocarcinoma.

The invention discloses application of crude extract of radix tetrastigme to preparation of a chemotherapeutic medicament for inhibiting the pancreatic cancer. The invention further discloses a medicament for inhibiting the pancreatic cancer. The medicament comprises one or more of four components as follows: a component-1 (10% (1-2) EtOH extract), a component-2 (10% (-3) to 30%(1-2) EtOH extract), a component-3(30%(-1) to 50%(-1) EtOH extract) and a component-4 (50%(-2) to 95%(-2) EtOH extract). The invention further discloses application of the crude extract of the radix tetrastigme in the aspect of inhibiting the pancreatic cancer. The application comprises the following process of: respectively implanting four types of pancreatic ductal adenocarcinoma (PDAC) cells into a 96-hole plate;carrying out cell adherence, and respectively adding four components of the crude extract of the radix tetrastigme; carrying out shooting under a fluorescence microscope; and measuring a cell survival rate by CCK-8. The invention additionally further provides a method for acquiring the crude extract of the radix tetrastigme. Application of the radix tetrastigme, which is disclosed by the invention, provides a new treatment target for the chemotherapeutic medicament and a treatment medicament for the pancreatic cancer.

The invention relates to an application of a bacillus subtilis protein AMEP412 with an amino acid sequence as shown in SEQ ID NO: 1 in inhibition of tumor cell proliferation. The tumor cells are any one of liver cancer cells, cervical cancer cells, pancreatic cancer cells, colon cancer cells, prostate cancer cells, lung cancer cells, uterine squamous cell carcinoma cells, gastric adenocarcinoma cells, malignant glioblastoma cells and breast cancer cells. According to the invention, the inhibition function of the protein AMEP412 on tumor cells is found; the protein can generate an inhibition effect on 10 kinds of tumor cells, has selective specificity on inhibition effects on different kinds of tumor cells, and has the best effect on breast cancer cells; transcriptomics research finds that the protein AMEP412 can cause the change of a plurality of pathways related to apoptosis and death in tumor cells, and a new material is accumulated for inhibiting the activity of the tumor cells.

The invention belongs to the fields of chemical engineering and medicaments and relates to application of 12-dehydroxy-21-hydroxy protopanoxadiol in preparation of antitumor medicaments. The invention provides the application of the 12-dehydroxy-21-hydroxy protopanoxadiol in preparation of the antitumor medicaments. Tumor cells comprise liver cancer, leukaemia, adenocarcinorma of lung or pancreatic cancer. The 12-dehydroxy-21-hydroxy protopanoxadiol belongs to natural products and has a certain clinical utilization value. A micromolecular compound provided by the invention as a new antitumor medicament or an assistant component of the medicament is developed; the antitumor effect is obvious; the micromolecular compound is environmental friendly; and the invention provides a new way and means for treating and curing tumors.

The invention discloses a heteroaryl compound and application thereof, and provides a heteroaryl compound as shown in a formula I, a tautomer, a stereoisomer or a pharmaceutically acceptable salt thereof. The compound has good tumor inhibition activity, especially on human chronic lymphocytic leukemia, lung adenocarcinoma, breast cancer, ovarian cancer, breast cancer or pancreatic cancer, and hasgood inhibitory activity on drug-resistant breast cancer, lung cancer, ovarian cancer or leukemia.

The invention discloses a semi-synthetic taxane derivative. An anti-tumor effect test shows that the semi-synthetic taxane derivative has relatively good anti-tumor activity on a human lung adenocarcinoma cell line A549, a human breast cancer cell line MCF-7, a human glioblastoma cell line U251, a human pancreatic cancer cell line PANC-1, a human colon cancer cell line HCT116 and a human non-small lung cancer cell line H460. The semi-synthetic taxane derivative can be used for preparing anti-tumor drugs.

The invention provides application of vilazodone or a derivative thereof and a pharmaceutical composition containing the vilazodone or the derivative thereof in preparation of drugs for preventing and / or treating tumors. The compound has an obvious growth inhibition effect on various human tumor cells, and particularly has an obvious inhibition effect on tumor growth of nude mice inoculated with human tumor cells; the vilazodone or derivative thereof has broad-spectrum antitumor activity, and has good inhibitory activity on breast cancer, colorectal cancer, ovarian cancer, lung cancer, liver cancer, gastric cancer, leukemia, lymphoma, melanoma, pancreatic cancer, esophagus cancer, thyroid cancer, cervical cancer, renal clear cell adenocarcinoma, glioma, nasopharynx cancer and other tumors; and experiments show that vilazodone and the derivative thereof can become antitumor drugs.

The invention discloses application of p38 gamma in preparation of a pancreatic cancer prognosis diagnostic reagent. The inventor finds that expression of p38 gamma in cancer tissues of a pancreatic cancer patient is remarkably higher than that of p38 gamma in normal tissues, the expression level of p38 gamma is gradually increased along with disease progression, and the high expression of p38 gamma is related to adverse prognosis of the patient. A pancreatic duct adenocarcinoma animal model K-RasG12D-p53R172H-Pdx-Cre (KPC) is constructed as a control group for research. A pancreatic ductal epithelial cell p38 gamma knockout pancreatic cancer animal model (KPC-p38 gamma-KO) is constructed as an experimental group by applying a Cre / LoxP technology. The p38 gamma knockout is found to be capable of remarkably reducing the size of a tumor and prolonging the lifetime of KPC mice. The median survival time of the mice in the KPC group is 160 days, most KPC-p38 gamma-KO mice still survive in the statistical time, and the median survival time is longer than 300 days. A further experimental result shows that high expression of p38 gamma can promote invasion and metastasis of a pancreatic cancer. Therefore, p38 gamma can well determine the risk and prognosis of the pancreatic cancer.

The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.

The invention relates to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combined treatment with a nucleoside analogue (preferably gemcitabine) and a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.

The invention discloses application of PLD1 as a molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs. The invention finds that the expression level of PLD1 in pancreatic ductal adenocarcinoma is related to the sensitivity to gemcitabine, the expression of PLD1 in pancreatic cancer tumor cell nucleuses is related to the differentiation degree and T staging of tumors, and the total lifetime of patients with high expression of PLD1 in cancer ductal cell nucleuses is short, which indicates that the patients with high expression of PLD1 in pancreatic cancer ductal cells are related to postoperative recurrence and metastasis, and the patients with high expression of PLD1 in pancreatic cancer ductal cells are related to postoperative recurrence and metastasis. The biomarker is used for estimating prognosis of pancreatic cancer patients, recurrence and metastasis of tumors and tumor differentiation degree. Therefore, the invention can guide clinical treatment of pancreatic ductal adenocarcinoma and reverse gemcitabine drug resistance. The PLD1 biomarker related to patient prognosis is found in a tissue specimen of a pancreatic cancer patient, so that the drug resistance degree of the patient to pre-gemcitabine can be evaluated more directly, objectively, timely and accurately, and the method is economical, rapid and more beneficial to actual operation.

The invention belongs to the technical field of medicine, discloses an anti-tumor quaternary ammonium salt derivative, a preparation method and application thereof, a series of anti-tumor derivativesprepared through corresponding chemical reactions, and the application of the derivatives in anti-tumor. The present invention shows that all synthetic diosgenin quaternary ammonium salt derivatives have obvious inhibitory effect on the proliferation of A549 lung cancer cells, H1975 lung adenocarcinoma cells, Aspc-1 metastatic pancreatic cancer cells and A431 skin squamous carcinoma cells, and theantitumor activity of most derivatives is better than that of diosgenin, and the antitumor activity of most derivatives is better than that of diosgenin on Ramos B lymphoma cells.

The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated.

The invention provides application of felotinib in inhibition of tumor proliferation of pancreatic cancer cells and mouse pancreatic cancer, namely application in preparation of products for inhibition of tumor proliferation of pancreatic cancer cells or mouse pancreatic cancer. The invention further provides a product for inhibiting tumor proliferation of adenocarcinoma cells or mouse pancreatic cancer. The product contains the felotinib with pharmacological effective concentration. The effective pharmacological concentration is not less than 12.5 [mu]mol / L; and the product is a liquid product. The invention finds that the non-lotinib can inhibit the proliferation of pancreatic cancer cells and mouse pancreatic cancer tumors, and the non-lotinib can be used for preparing a novel medicine for treating pancreatic cancer.

The invention relates to the field of medicinal chemistry, and in particular, relates to an application of a brefeldin A ester derivative in the aspect of inhibiting tumor proliferation activity; the brefeldin A ester derivative can be used for preventing or treating hyperproliferative diseases, and the structure of the brefeldin A ester derivative is represented by a formula (I). Hyperproliferative diseases comprise liver cancer, leukemia, breast cancer, colonic adenocarcinoma, gastric cancer, lung cancer, Bartter's esophagus cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymph cancer, kidney cancer, brain cancer, nerve cancer, nasopharynx cancer, oral cancer and colorectal cancer, so that the brefeldin A ester derivative has the potential of being developed into a novel antitumor drug.